Login to Your Account

Zealand Signs Helsinn to €140M Deal for GLP-2 Agonist in CID

By Jennifer Boggs

Wednesday, December 3, 2008

No Abstract


Assistant Managing Editor

Danish biotech firm Zealand Pharma A/S partnered with Helsinn Healthcare in a potential €140 million (US$176.8 million) deal to develop its early clinical-stage glucagon-like peptide (GLP)-2 receptor agonist, ZP1846, in chemotherapy-induced diarrhea (CID).

Under the terms, Zealand granted Helsinn worldwide rights to the compound, except for the Nordic countries, where Zealand retains marketing rights.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription